Anapharm
12
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
8%
1 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers
Role: collaborator
Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants
Role: collaborator
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions
Role: collaborator
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions
Role: collaborator
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions
Role: collaborator
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions
Role: collaborator
Bioavailability Study of Torsemide Tablets Under Fasting Conditions
Role: collaborator
Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers
Role: collaborator
Bioavailability Study of Torsemide Tablets Under Fed Conditions
Role: collaborator
Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions
Role: collaborator
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions
Role: collaborator
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions
Role: collaborator
All 12 trials loaded